Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | TYR | P14679 | 5/20 | 0.46 |
| ▸ | IGF1R | P08069 | 7/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oregonin SCHEMBL12659728 | 0.83 | PPARG (0.46) | PPARGPPARDPPARATYR | |
| Oregonin SCHEMBL29389089 | 0.83 | PPARG (0.46) | PPARGPPARDPPARATYR | |
| Alnuside B SCHEMBL22796510 | 0.79 | PPARG (0.49) | PPARGPPARDPPARATYR | |
| Alnuside B SCHEMBL12672476 | 0.79 | PPARG (0.49) | PPARGPPARDPPARATYR | |
| SCHEMBL22796348 | 0.75 | PPARG (0.40) | PPARGPPARDPPARATYR | |
| SCHEMBL12659725 | 0.68 | PPARG (0.40) | PPARGPPARDPPARATYRIGF1R | |
| SCHEMBL26361996 | 0.66 | ALOX15 (0.63) | IGF1RALOX15 | |
| SCHEMBL2307446 | 0.66 | ALOX15 (1.00) | IGF1RALOX15 | |
| SCHEMBL10966306 | 0.66 | TYR (0.39) | TYR | |
| SCHEMBL14790112 | 0.66 | ALOX15 (0.68) | PPARGPPARDPPARAIGF1RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105738-A1 | DIARYL HEPATONOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS | RNL BIO CO., LTD. (KR) | 2011-05-05 | — | — | US | disclosed |
| US-20110105738-A1 | DIARYL HEPATONOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS | RNL BIO CO., LTD. (KR) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105738-A1 | DIARYL HEPATONOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS | HAVCR2, CYP7A1, CYP51A1 | PPARG 4555/4885PPARD 4087/4885PPARA 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.